RUBICON ORGANICS INC (ROMJ.CA) Stock Fundamental Analysis
Canada - TSX-V:ROMJ - CA78112W1005 - Common Stock
0.495 CAD
0 (0%)
We assign a fundamental rating of 6 out of 10 to ROMJ. ROMJ was compared to 31 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of ROMJ get a neutral evaluation. Nothing too spectacular is happening here. ROMJ is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes ROMJ very considerable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year ROMJ has reported negative net income.
ROMJ had a positive operating cash flow in the past year.
In the past 5 years ROMJ always reported negative net income.
In multiple years ROMJ reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a decent Return On Assets value of 0.38%, ROMJ is doing good in the industry, outperforming 70.97% of the companies in the same industry.
The Return On Equity of ROMJ (0.55%) is better than 67.74% of its industry peers.
ROMJ has a Return On Invested Capital of 21.14%. This is amongst the best in the industry. ROMJ outperforms 100.00% of its industry peers.
ROMJ had an Average Return On Invested Capital over the past 3 years of 19.33%. This is significantly above the industry average of 7.71%.
The 3 year average ROIC (19.33%) for ROMJ is below the current ROIC(21.14%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.38% | ||
| ROE | 0.55% | ||
| ROIC | 21.14% |
ROA(3y)-4.91%
ROA(5y)-14.11%
ROE(3y)-7.24%
ROE(5y)-22.2%
ROIC(3y)19.33%
ROIC(5y)N/A
1.3 Margins
ROMJ has a better Profit Margin (0.43%) than 67.74% of its industry peers.
ROMJ's Operating Margin of 27.18% is amongst the best of the industry. ROMJ outperforms 100.00% of its industry peers.
Looking at the Gross Margin, with a value of 59.50%, ROMJ belongs to the top of the industry, outperforming 87.10% of the companies in the same industry.
In the last couple of years the Gross Margin of ROMJ has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.18% | ||
| PM (TTM) | 0.43% | ||
| GM | 59.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ROMJ has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for ROMJ has been increased compared to 1 year ago.
The number of shares outstanding for ROMJ has been increased compared to 5 years ago.
Compared to 1 year ago, ROMJ has an improved debt to assets ratio.
2.2 Solvency
ROMJ has an Altman-Z score of 1.57. This is a bad value and indicates that ROMJ is not financially healthy and even has some risk of bankruptcy.
With an excellent Altman-Z score value of 1.57, ROMJ belongs to the best of the industry, outperforming 83.87% of the companies in the same industry.
A Debt/Equity ratio of 0.19 indicates that ROMJ is not too dependend on debt financing.
ROMJ's Debt to Equity ratio of 0.19 is in line compared to the rest of the industry. ROMJ outperforms 54.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.57 |
ROIC/WACC2.4
WACC8.81%
2.3 Liquidity
A Current Ratio of 2.92 indicates that ROMJ has no problem at all paying its short term obligations.
With an excellent Current ratio value of 2.92, ROMJ belongs to the best of the industry, outperforming 80.65% of the companies in the same industry.
A Quick Ratio of 1.46 indicates that ROMJ should not have too much problems paying its short term obligations.
ROMJ's Quick ratio of 1.46 is in line compared to the rest of the industry. ROMJ outperforms 58.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.92 | ||
| Quick Ratio | 1.46 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 104.07% over the past year.
Looking at the last year, ROMJ shows a very strong growth in Revenue. The Revenue has grown by 34.19%.
Measured over the past years, ROMJ shows a very strong growth in Revenue. The Revenue has been growing by 29.14% on average per year.
EPS 1Y (TTM)104.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%246.25%
Revenue 1Y (TTM)34.19%
Revenue growth 3Y29.14%
Revenue growth 5YN/A
Sales Q2Q%23.78%
3.2 Future
Based on estimates for the next years, ROMJ will show a very strong growth in Earnings Per Share. The EPS will grow by 91.29% on average per year.
Based on estimates for the next years, ROMJ will show a very strong growth in Revenue. The Revenue will grow by 28.51% on average per year.
EPS Next Y100%
EPS Next 2Y96.85%
EPS Next 3Y91.29%
EPS Next 5YN/A
Revenue Next Year22.82%
Revenue Next 2Y24.16%
Revenue Next 3Y28.51%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Forward Earnings ratio of 6.53, the valuation of ROMJ can be described as very cheap.
Based on the Price/Forward Earnings ratio, ROMJ is valued cheaply inside the industry as 90.32% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 31.86. ROMJ is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 6.53 |
4.2 Price Multiples
100.00% of the companies in the same industry are more expensive than ROMJ, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.95 |
4.3 Compensation for Growth
ROMJ's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of ROMJ may justify a higher PE ratio.
ROMJ's earnings are expected to grow with 91.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y96.85%
EPS Next 3Y91.29%
5. Dividend
5.1 Amount
ROMJ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:ROMJ (11/5/2025, 7:00:00 PM)
0.495
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners3.22%
Inst Owner ChangeN/A
Ins Owners42.42%
Ins Owner ChangeN/A
Market Cap33.25M
Revenue(TTM)55.06M
Net Income(TTM)235.20K
Analysts80
Price Target1.17 (136.36%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.54%
PT rev (3m)4.55%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)150%
EPS NY rev (1m)N/A
EPS NY rev (3m)100%
Revenue NQ rev (1m)-1.27%
Revenue NQ rev (3m)12.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)13.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 6.53 | ||
| P/S | 0.6 | ||
| P/FCF | N/A | ||
| P/OCF | 11.01 | ||
| P/B | 0.78 | ||
| P/tB | 0.82 | ||
| EV/EBITDA | 1.95 |
EPS(TTM)0
EYN/A
EPS(NY)0.08
Fwd EY15.3%
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)0.04
OCFY9.09%
SpS0.82
BVpS0.64
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.38% | ||
| ROE | 0.55% | ||
| ROCE | 29.36% | ||
| ROIC | 21.14% | ||
| ROICexc | 24.66% | ||
| ROICexgc | 26.08% | ||
| OM | 27.18% | ||
| PM (TTM) | 0.43% | ||
| GM | 59.5% | ||
| FCFM | N/A |
ROA(3y)-4.91%
ROA(5y)-14.11%
ROE(3y)-7.24%
ROE(5y)-22.2%
ROIC(3y)19.33%
ROIC(5y)N/A
ROICexc(3y)24.75%
ROICexc(5y)N/A
ROICexgc(3y)26.66%
ROICexgc(5y)N/A
ROCE(3y)26.85%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5YN/A
F-Score7
Asset Turnover0.89
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.45 | ||
| Cap/Depr | 204.1% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 13.51 | ||
| Cash Conversion | 16.58% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.92 | ||
| Quick Ratio | 1.46 | ||
| Altman-Z | 1.57 |
F-Score7
WACC8.81%
ROIC/WACC2.4
Cap/Depr(3y)93.56%
Cap/Depr(5y)171.69%
Cap/Sales(3y)7.51%
Cap/Sales(5y)22.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)104.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%246.25%
EPS Next Y100%
EPS Next 2Y96.85%
EPS Next 3Y91.29%
EPS Next 5YN/A
Revenue 1Y (TTM)34.19%
Revenue growth 3Y29.14%
Revenue growth 5YN/A
Sales Q2Q%23.78%
Revenue Next Year22.82%
Revenue Next 2Y24.16%
Revenue Next 3Y28.51%
Revenue Next 5YN/A
EBIT growth 1Y59.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-71.19%
EBIT Next 3Y4.44%
EBIT Next 5YN/A
FCF growth 1Y-210.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.26%
OCF growth 3YN/A
OCF growth 5YN/A
RUBICON ORGANICS INC / ROMJ.CA FAQ
What is the fundamental rating for ROMJ stock?
ChartMill assigns a fundamental rating of 6 / 10 to ROMJ.CA.
What is the valuation status for ROMJ stock?
ChartMill assigns a valuation rating of 6 / 10 to RUBICON ORGANICS INC (ROMJ.CA). This can be considered as Fairly Valued.
What is the profitability of ROMJ stock?
RUBICON ORGANICS INC (ROMJ.CA) has a profitability rating of 6 / 10.